CYP3A5 Polymorphism In Serbian Paediatric Epileptic Patients On Carbamazepine Treatment

1. Abraham S, Shaju M. Innovations in epilepsy management - an overview. J Pharm Pharm Sci 2013; 16(4):564-76.10.18433/J32K5BSearch in Google Scholar

2. Atlas: Epilepsy Care in the World. Geneva, Switzerland: World Health Organization; 2005. 91p.Search in Google Scholar

3. Magiorkinis E, Diamantis A, Sidiropoulou K, Panteliadis C. Highights in the history of epilepsy: the last 200 years. Epilepsy Res Treat 2014; 2014:582039.10.1155/2014/582039Search in Google Scholar

4. Simonato M, French JA, Galanopoulou AS, O’Brien TJ. Issues for new antiepilepsy drug development. Curr Opin Neurol 2013; 26(2):195-200.10.1097/WCO.0b013e32835efe29Search in Google Scholar

5. Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014; 37C:59-70.10.1016/j.yebeh.2014.05.031Search in Google Scholar

6. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50(1):1-23.10.1111/j.1528-1167.2008.01716.xSearch in Google Scholar

7. Thorn CF, Leckband SG, Kelsoe J, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011; 21(12):906-10.10.1097/FPC.0b013e328348c6f2Search in Google Scholar

8. Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol 2008; 30(9):707-13.10.1358/mf.2008.30.9.1323496Search in Google Scholar

9. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47(11):1969-79.10.1016/0006-2952(94)90071-XSearch in Google Scholar

10. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 2013; 138:103-41.10.1016/j.pharmthera.2012.12.00723333322Search in Google Scholar

11. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13:461–472.10.1097/00008571-200308000-0000412893984Search in Google Scholar

12. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-54.10.1016/S0009-9236(03)00168-1Search in Google Scholar

13. Jin Y, Wang YH, Miao J, et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007; 82:579–85.10.1038/sj.clpt.610020817443134Search in Google Scholar

14. Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007; 81:708-12.10.1038/sj.clpt.610011717329995Search in Google Scholar

15. Park PW, Seo YH, Ahn JY, et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34(5):569-574.10.1111/j.1365-2710.2009.01057.x19744012Search in Google Scholar

16. Meng H, Ren J, Lv Y, et al. Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients. Neurology Asia 2011; 16(1):39-45.Search in Google Scholar

17. Seo T, Nakada N, Ueda N, et al. Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ther 2006; 79(5):509-10.10.1016/j.clpt.2006.02.00916678552Search in Google Scholar

18. Puranik YG, Birnbaum AK, Marino SE, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 2013; 14(1):35-45.10.2217/pgs.12.180357004823252947Search in Google Scholar

19. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006; 45(10):957-64.10.2165/00003088-200645100-0000116984210Search in Google Scholar

20. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84(3):417-23.10.1038/clpt.2008.14118615002Search in Google Scholar

21. Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J. Toxicol. Sci. 2009; 34(II):SP307-SP312.10.2131/jts.34.SP307Search in Google Scholar

22. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48(10):1668-71.10.1093/clinchem/48.10.1668Search in Google Scholar

23. King BP, Leathart JB, Mutch E, et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55(6):625-9.10.1046/j.1365-2125.2003.01798.x188424712814460Search in Google Scholar

24. Sweetman S, ed. Martindale: The complete drug reference 36. Pharmaceutical Press; 2009.Search in Google Scholar

25. Spurr NK, Gough AC, Stevenson K, Wolf CR. The human cytochrome P450 CYP3A locus: assignment to chromosome 7g22-qter. Hum Genet 1989; 81(2):171-4.10.1007/BF002938962563251Search in Google Scholar

26. Chen X, Wang HW, Zhou G, et al. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine. Environmental Health Perspectives 2009; 117(10):1541-8.10.1289/ehp.0800528279050820019904Search in Google Scholar

27. Xie HG, Wood AJJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5(3):243–272.10.1517/phgs.5.3.243.2983315102541Search in Google Scholar

28. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.10.1038/8688211279519Search in Google Scholar

29. Hiratsuka M, Takekuma Y, Endo N, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002; 58:417-421.10.1007/s00228-002-0499-512242601Search in Google Scholar

30. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.10.1097/00008571-200112000-0000511740341Search in Google Scholar

31. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) 2003; 95(3):1297-300.10.1152/japplphysiol.00322.200312754175Search in Google Scholar

32. Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 2010; 31(2):95-103.10.1159/000258688285359119907160Search in Google Scholar

33. Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005; 353:187–192.10.1016/j.cccn.2004.11.00515698606Search in Google Scholar

34. Saeki M, Saito Y, Nakamura T, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 2003; 618:1-7.Search in Google Scholar

35. Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2007; 21(4):419-26.10.1111/j.1472-8206.2007.00510.x17635181Search in Google Scholar

36. Hilli J, Rane A, Lundgren S, et al. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundamental & Clinical Pharmacology 2007; 21:379–86.10.1111/j.1472-8206.2007.00494.x17635176Search in Google Scholar

37. Borst L, Wallerek S, Dalhoff K, et al. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol 2011; 86(477–83).10.1111/j.1600-0609.2011.01608.x21418106Search in Google Scholar

38. Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev 2010; 11(781-4).Search in Google Scholar

39. Shimada N, Iwasaki M, Kasuga Y, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 2009; 54(209-15).10.1038/jhg.2009.1319229255Search in Google Scholar

40. Mefford HC. CNVs in Epilepsy. Curr Genet Med Rep 2014; 2:162-167.10.1007/s40142-014-0046-6412922525152848Search in Google Scholar

41. Helbig I, Lowenstein DH. Genetics of the epilepsies: where are we and where are we going? Curr Opin Neurol 2013; 26(2):179-85.Search in Google Scholar

42. Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80:646-56.10.1016/j.clpt.2006.09.00917178265Search in Google Scholar

43. Kim KA, Park PW, Lee OJ, et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47:87-93.10.1177/009127000629506317192506Search in Google Scholar

44. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004; 60:231-6.10.1007/s00228-004-0767-715114431Search in Google Scholar

45. Fukuda T, Onishi S, Fukuen S, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004; 4(1):34-9.10.1038/sj.tpj.650021814647405Search in Google Scholar

46. Yamamoto T, Kubota T, Ozeki T, et al. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Clin Chim Acta 2005; 362(1-2):147-54.10.1016/j.cccn.2005.06.01316024008Search in Google Scholar

47. Emich-Widera E, Likus W, Kazek B, et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int 2013; 2013:526837.10.1155/2013/526837Search in Google Scholar

48. Semiz S, Dujic T, Ostanek B, et al. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina. Med Glas (Zenica) 2011; 8:84-9.Search in Google Scholar

49. Jakovski K, Kapedanovska Nestorovska A, Labacevski N, Dimovski AJ. Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. Macedonian pharmaceutical bulletin 2012; 58(1,2):25-30.10.33320/maced.pharm.bull.2012.58.003Search in Google Scholar

50. Turolo S, Tirelli AS, Ferraresso M, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62:1159–69.10.1016/S1734-1140(10)70378-9Search in Google Scholar

51. Adler G, Loniewska B, Parczewski M, et al. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep 2009; 61:947–51.10.1016/S1734-1140(09)70154-9Search in Google Scholar

52. Bosch TM, Doodeman VD, Smits PHM, et al. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diag Ther 2006; 10(3):175-185.10.1007/BF0325645616771603Search in Google Scholar

53. Seredina TA, Goreva OB, Talaban VO, et al. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med. Genet 2012; 13:45.Search in Google Scholar

54. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004; 75(6):529-38.10.1016/j.clpt.2004.02.00515179407Search in Google Scholar

55. Djordjevic N, Jankovic S, Bertilsson L, Aklillu E. CYP3A4 i CYP3A5 genetski polimorfizam kod Srba. Med Cas 2008; 42(1):Suppl 1: 29.Search in Google Scholar

56. Stefanovic N, Cvetkovic T, Velickovic-Radovanovic R, et al. Significance of CYP3A5 gene polymorphism in Serbian renal transplant patients. Acta Medica Medianae 2013; 52(1):33-8.10.5633/amm.2013.0105Search in Google Scholar

57. Balram C, Zhou Q, Cheung YB, Lee EJD. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003; 59:123–126.10.1007/s00228-003-0594-212756511Search in Google Scholar

58. Liu CH, Peck K, Huang JD, et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005; 6(7):731-47.10.2217/14622416.6.7.73116207150Search in Google Scholar